Core Viewpoint - The recent transfer of shares of 开拓药业-B (09939) indicates a strategic shift among shareholders, with a significant market value of HKD 64.43 million being moved, representing 6.49% of the total shares [1] Group 1: Shareholder Activity - On October 15, shareholders of 开拓药业-B transferred their shares from 富途证券国际香港 to 艾德证券期货, with a total market value of HKD 64.43 million [1] - This transfer accounts for 6.49% of the company's total shares, suggesting a notable shift in shareholder strategy [1] Group 2: Product Development - 开拓药业-B has completed the enrollment of 130 participants in the long-term safety trial for its self-developed tyrosinase inhibitor KT-939 [1] - KT-939 is designed to effectively inhibit melanin production by precisely targeting tyrosinase, blocking the oxidation process of tyrosine [1] - The product also boasts antioxidant and anti-inflammatory properties, providing significant advantages in both efficacy and safety for cosmetic applications [1]
开拓药业-B(09939)股东将股票由富途证券国际香港转入艾德证券期货 转仓市值6443.21万港元